Evaluating the efficacy of adding rivastigmin to a selective serotonin re-uptake inhibitor,Sertraline, in the treatment of major depressive disorder :a pilot study

Vice chancellor for research, Mazandaran University of Medical Sciences0 个研究点目标入组 20 人开始时间: 待定最近更新: 2018年2月22日

试验速览

暂无简介。

•All outpatients with Major Depressive Disorder based on DSM-IV-TR in the age range of 25-55 year old who refer to psychiatric clinic in Imam khomeini hospital clinic.
•Exclusions criteria:
•Psychiatric comorbidity(primary or secondary diagnosis of bipolar I disorder, either manic or mixed episode, as defined by DSM-V);History of substance dependence (including alcohol, but excluding nicotine) as defined by DSM-V and relapse within the past 6 months, or substance abuse within the 3 months preceding the trial or positive urine test for illicit drugs;Electroconvulsive therapy during the 6 past months;Suicidality(active suicide or homicide intent, or a suicide or homicide attempt in the preceding 6 months);Mental retardation;Pregnant or at risk of pregnancy;Cognitive disorders such as dementia, delirium, or amnesia, traumatic brain injury;Current significant unstable medical illness (such as unstable cardiac disease, hepatic or renal impairment, evidence or history of malignancy or any significant hematological, endocrine)/ HIV infection / abnormalities on physical examination, vital signs, electrocardiogram (ECG), or clinical laboratory values;Hypersensitivity to rivastigmin;Previous treatment with rivastigmin in the past year;History of neuroleptic malignant syndrome;Patients under treatment cholinesterase inhibitors, N-methyl D-aspartate (NMDA) receptor antagonists;Unwilling or unable, in the opinion of the Investigator, to comply with study instructions

发起方

Vice chancellor for research, Mazandaran University of Medical Sciences